TY - JOUR
T1 - The clinical spectrum of RET proto-oncogene mutations in codon 790
AU - Bihan, Helene
AU - Murat, Arnaud
AU - Fysekidis, Marinos
AU - Al-Salameh, Abdallah
AU - Schwartz, Claire
AU - Baudin, Eric
AU - Thieblot, Philippe
AU - Borson-Chazot, Francoise
AU - Guillausseau, Pierre Jean
AU - Cardot-Bauters, Catherine
AU - Raingeard, Isabelle
AU - Requeda, Elisabeth
AU - Sadoul, Jean Louis
AU - Reznik, Yves
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Objective: Due to a strong genotype-phenotype correlation, the timing of prophylactic thyroidectomy in rearranged during transfection (RET) gene mutation carriers is usually dictated by genetic analysis. Subjects and methods: We report a nationwide retrospective study of the clinical data of 77 French patients from 19 families with a mutation in codon 790 of the RET proto-oncogene. Results: The average age at diagnosis was 35.6 yearsG20.5. Thirty-nine patients were women. Fiftyfive patients underwent operations for the treatment of medullary thyroid carcinoma (MTC) at the mean age of 38 years (4-82 years). The mean follow-up duration was 89 months. TNM staging was as follows: T0NxMx in 19, TxNxMx in 1, T1NxMx in 22, T1N1Mx in 8, T2N1Mx in 1 and T3N1Mx in four patients. In the T1/x-Nx group, 96% were considered cured after surgery. In the N1 group (nZ13), six patients had multifocal disease and five patients were cured. Age and gender were not significant predictors of remission. Twenty-two patients did not undergo an operation (age 1.5-78 years); among them, 11 patients had a mean basal calcitonin (CT) level of 9.8 pg/ml (2-24) after 53 months of follow-up. One patient had been operated on for phaeochromocytoma (PHEO), and their CT level remained normal for 262 months. Conclusions: This study confirms that RET 790 mutation is associated with a non-aggressive form of multiple endocrine neoplasia type 2, as 28% of the patients were followed up without thyroidectomy, 25% had been thyroidectomised with no tumour being detected and even patients with MTC had slowevolving disease. Moreover, only one patient had PHEO, and no-one had primary hyperparathyroidism.
AB - Objective: Due to a strong genotype-phenotype correlation, the timing of prophylactic thyroidectomy in rearranged during transfection (RET) gene mutation carriers is usually dictated by genetic analysis. Subjects and methods: We report a nationwide retrospective study of the clinical data of 77 French patients from 19 families with a mutation in codon 790 of the RET proto-oncogene. Results: The average age at diagnosis was 35.6 yearsG20.5. Thirty-nine patients were women. Fiftyfive patients underwent operations for the treatment of medullary thyroid carcinoma (MTC) at the mean age of 38 years (4-82 years). The mean follow-up duration was 89 months. TNM staging was as follows: T0NxMx in 19, TxNxMx in 1, T1NxMx in 22, T1N1Mx in 8, T2N1Mx in 1 and T3N1Mx in four patients. In the T1/x-Nx group, 96% were considered cured after surgery. In the N1 group (nZ13), six patients had multifocal disease and five patients were cured. Age and gender were not significant predictors of remission. Twenty-two patients did not undergo an operation (age 1.5-78 years); among them, 11 patients had a mean basal calcitonin (CT) level of 9.8 pg/ml (2-24) after 53 months of follow-up. One patient had been operated on for phaeochromocytoma (PHEO), and their CT level remained normal for 262 months. Conclusions: This study confirms that RET 790 mutation is associated with a non-aggressive form of multiple endocrine neoplasia type 2, as 28% of the patients were followed up without thyroidectomy, 25% had been thyroidectomised with no tumour being detected and even patients with MTC had slowevolving disease. Moreover, only one patient had PHEO, and no-one had primary hyperparathyroidism.
UR - http://www.scopus.com/inward/record.url?scp=84883386409&partnerID=8YFLogxK
U2 - 10.1530/EJE-13-0050
DO - 10.1530/EJE-13-0050
M3 - Article
C2 - 23756355
AN - SCOPUS:84883386409
SN - 0804-4643
VL - 169
SP - 271
EP - 276
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -